Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis

Bioconjugate Chemistry

Volumn 25, Issue 12, 2014, Pages 2212-2221

  Byeon, Hyeong Jun ^a   Min, Sun Young ^a   Kim, Insoo ^a   Lee, Eun Seong ^b   Oh, Kyung Taek ^c   Shin, Beom Soo ^d   Lee, Kang Choon ^a   Youn, Yu Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Chung Ang University   (South Korea)

^d Catholic University of Daegu   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; CELL DEATH; MAMMALS; PROTEINS;

ANTIPROLIFERATION; BI-FUNCTIONAL; COLLAGEN-INDUCED ARTHRITIS; HUMAN SERUM ALBUMINS; IN-VIVO; LIFESPANS; MOLECULAR SIZE; RHEUMATOID ARTHRITIS; TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGANDS; TUMOR-NECROSIS FACTOR-RELATED APOPTOSIS INDUCING LIGAND;

DISEASES;

COLLAGEN TYPE 2; CYTOKINE; GAMMA INTERFERON; HUMAN SERUM ALBUMIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; MACROGOL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTIRHEUMATIC AGENT; COLLAGEN; SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; ERYTHEMA; HIND PAW; HINDLIMB; IN VITRO STUDY; IN VIVO STUDY; JOINT SWELLING; MALE; MOLECULAR SIZE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SERUM; SPLEEN CELL; SYSTEMIC CIRCULATION; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CHEMISTRY; DBA MOUSE; DRUG EFFECTS; HUMAN; METABOLISM; SPLEEN; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

AGOUTI PACA; MUS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COLLAGEN; CYTOKINES; HUMANS; MALE; MICE, INBRED DBA; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; SPLEEN; TISSUE DISTRIBUTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84918531394     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc500427g     Document Type: Article

References (36)

1. Smolen, J. S., and Steiner, G. (2003) Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discovery 2, 473-88.
2. Stoll, J. G., and Yasothan, U. (2009) Rheumatoid arthritis market. Nat. Rev. Drug Discovery 8, 693-4.
3. Gabriel, S. E. (2001) The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 27, 269-81.
4. Scott, D. L. (2012) Biologics-based therapy for the treatment of rheumatoid arthritis. Clin. Pharmacol. Ther. 91, 30-43.
5. Luis, M. L., and Alberto, A. (2012) Role of Apo2L/TRAIL in immunity: Applications to rheumatoid arthritis. World J. Rheumatol. 2, 1-11.
6. Fesik, S. W. (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5, 876-85.
7. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-90.
8. Almasan, A., and Ashkenazi, A. (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14, 337-48.
9. Tsokos, G. C., and Tsokos, M. (2003) The TRAIL to arthritis. J. Clin. Invest. 112, 1315-7.
10. Neve, A., Corrado, A., and Cantatore, F. P. (2014) TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what's new? Clin. Exp. Med. 14, 115-20.
11. Jin, C. H., Chae, S. Y., Kim, T. H., Yang, H. K., Lee, E. Y., Song, Y. W., Jo, D. G., and Lee, K. C. (2010) Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis. J. Pharmacol. Exp. Ther. 332, 858-65.
12. Kim, Y. J., Chae, S. Y., Jin, C. H., Sivasubramanian, M., Son, S., Choi, K. Y., Jo, D. G., Kim, K., Chan Kwon, I., Lee, K. C., and Park, J. H. (2010) Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis. Biomaterials 31, 9057-64.
13. Song, K., Chen, Y., Goke, R., Wilmen, A., Seidel, C., Goke, A., Hilliard, B., and Chen, Y. (2000) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191, 1095-104.
14. Kratz, F. (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Controlled Release 132, 171-83.
15. Elsadek, B., and Kratz, F. (2012) Impact of albumin on drug delivery-new applications on the horizon. J. Controlled Release 157, 4-28.
16. Lee, J., Lee, C., Kim, I., Moon, H. R., Kim, T. H., Oh, K. T., Lee, E. S., Lee, K. C., and Youn, Y. S. (2012) Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia. Int. J. Pharm. 424, 50-7.
17. Kim, I., Kim, T. H., Ma, K., Lee, E. S., Kim, D., Oh, K. T., Lee, D. H., Lee, K. C., and Youn, Y. S. (2010) Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy. Bioconjugate Chem. 21, 1513-9.
18. Subramanian, G. M., Fiscella, M., Lamouse-Smith, A., Zeuzem, S., and McHutchison, J. G. (2007) Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 25, 1411-9.
19. Kratz, F., and Beyer, U. (1998) Serum proteins as drug carriers of anticancer agents: a review. Drug Delivery 5, 281-99.
20. Wilkinson, P., Jeremy, R., Brooks, F. P., and Hollander, J. L. (1965) The Mechanism of Hypoalbuminemia in Rheumatoid Arthritis. Ann. Int. Med. 63, 109-14.
21. Wunder, A., Muller-Ladner, U., Stelzer, E. H., Funk, J., Neumann, E., Stehle, G., Pap, T., Sinn, H., Gay, S., and Fiehn, C. (2003) Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J. Immunol. 170, 4793-801.
22. Levick, J. R. (1981) Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum. 24, 1550-60.
23. Kim, T. H., Youn, Y. S., Jiang, H. H., Lee, S., Chen, X., and Lee, K. C. (2011) PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects. Bioconjugate Chem. 22, 1631-7.
24. Morel, J., Audo, R., Hahne, M., and Combe, B. (2005) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 280, 15709-18.
25. Miyashita, T., Kawakami, A., Nakashima, T., Yamasaki, S., Tamai, M., Tanaka, F., Kamachi, M., Ida, H., Migita, K., Origuchi, T., Nakao, K., and Eguchi, K. (2004) Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin. Exp. Immunol. 137, 430-6.
26. Ichikawa, K., Liu, W., Fleck, M., Zhang, H., Zhao, L., Ohtsuka, T., Wang, Z., Liu, D., Mountz, J. D., Ohtsuki, M., Koopman, W. J., Kimberly, R., and Zhou, T. (2003) TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J. Immunol. 171, 1061-9.
27. Chae, S. Y., Kim, T. H., Park, K., Jin, C. H., Son, S., Lee, S., Youn, Y. S., Kim, K., Jo, D. G., Kwon, I. C., Chen, X., and Lee, K. C. (2010) Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer Ther. 9, 1719-29.
28. Kim, T. H., Jo, Y. G., Jiang, H. H., Lim, S. M., Youn, Y. S., Lee, S., Chen, X., Byun, Y., and Lee, K. C. (2012) PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. J. Controlled Release 162, 422-8.
29. Bae, S., Ma, K., Kim, T. H., Lee, E. S., Oh, K. T., Park, E. S., Lee, K. C., and Youn, Y. S. (2012) Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 33, 1536-46.
30. Temming, K., Meyer, D. L., Zabinski, R., Dijkers, E. C., Poelstra, K., Molema, G., and Kok, R. J. (2006) Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjugate Chem. 17, 1385-94.
31. Jiang, H. H., Kim, T. H., Lee, S., Chen, X., Youn, Y. S., and Lee, K. C. (2011) PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials 32, 8529-37.
32. Byeon, H. J., Choi, S. H., Choi, J. S., Kim, I., Shin, B. S., Lee, E. S., Park, E. S., Lee, K. C., and Youn, Y. S. (2014) Four-arm PEG crosslinked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer. Acta Biomater. 10, 142-50.
33. Byeon, H. J., Choi, S. H., Choi, J. S., Kim, T. H., Lee, E. S., Lee, K. C., and Youn, Y. S. (2014) Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model. Biomed. Pharmacother. 68, 65-9.
34. Kwok, S. K., Park, M. K., Cho, M. L., Oh, H. J., Park, E. M., Lee, D. G., Lee, J., Kim, H. Y., and Park, S. H. (2012) Retinoic acid attenuates rheumatoid inflammation in mice. J. Immunol. 189, 1062-71.
35. Camps, M., Ruckle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Francon, B., Martin, T., Gretener, D., Perrin, D., Leroy, D., Vitte, P. A., Hirsch, E., Wymann, M. P., Cirillo, R., Schwarz, M. K., and Rommel, C. (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936-43.
36. Kim, I., Byeon, H. J., Kim, T. H., Lee, E. S., Oh, K. T., Shin, B. S., Lee, K. C., and Youn, Y. S. (2013) Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials 34, 6444-53.